Pharma Industry News
Printable Version   Email to a friend

Segal Survey Predicts Continued Declines in All Trends -- Rx Trend Drops to Single Digits

NEW YORK--(BUSINESS WIRE)--Aug 21, 2008 - The 2009 Segal Health Plan Cost Trend Survey forecasts continued declines in trends for 2009, marking the sixth consecutive year of declining trends. Most trend rates are projected to be lower in 2009 than in 2008, but cost trends for all medical plan types are higher than inflation. Key findings include:

-- Projected trend rates for point-of-service (POS) medical plans (without prescription drugs) for actives and retirees under age 65 have declined from a high of 13.7% for 2003 to 10.4% for 2009.

-- Projected retail prescription drug trends continue to decline, and have fallen from a high of 19.7% in 2001 for active employees to 9.8% for 2009. For retirees, retail Rx trend has fallen to 9.1% in 2009. This is the first time since the survey's inception that prescription drug trends are in single digits.

-- Trend rates for hospital services are projected to be 10.9% in 2009, exceeding trends for physician services and prescription drug supplies.

-- Projected medical plan trend rates for retirees age 65 and older are expected to be measurably lower than the medical plan trend rates projected for active participants and early retirees.

-- Combined PPO and POS plan projected trend rates show variation among regions - Midwest trends are projected to be 9.4% compared to 10.0% for the South, 10.5% for the Northeast and 10.6% for the West.

According to Edward A. Kaplan, Segal's National Health Practice Leader, "We are seeing plan sponsors turning to innovative designs and health improvement programs as a vehicle for containing health plan costs through cost effective treatments, reducing complications from chronic disease and lowering demand for health services. The most effective strategies include mining data to identify a plan's cost drivers, redesigning plan provisions to eliminate barriers to care and providing incentives to comply with recommended care for specific diseases."

See how trend rates have changed since 2000: http://www.segalco.com/2009trendsurveysupplement.pdf.

The complete Survey can be found at: www.segalco.com/publications/surveysandstudies/2009trendsurvey.pdf.

The Segal Company (www.segalco.com) is an independent, US-based firm of benefit, compensation and human resources consultants. Clients include corporations, non-profit organizations, professional service firms, state and local governments and joint boards of trustees administering pension and health and welfare plans under the Taft-Hartley Act.

Contact

The Segal Company
Mary L. Feldman, 212-251-5029
mfeldman@segalco.com

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
December 2, 2008
Audience: Hematological and Nephrological healthcare professionals, hospital risk managers [Posted 12/02/2008] FDA has received...
December 2, 2008
Audience: Oncologists, other healthcare professionals[UPDATE 12/02/2008] FDA issued Q&As for recently approved Medication...
November 26, 2008
Audience: Consumers, healthcare professionals [Posted 11/26/2008] Balanced Health Products, Inc. announced a recall of STARCAPS...
November 26, 2008
Audience: Consumers, healthcare professionals [Posted 11/26/2008] Fashion Sanctuary announced a recall of Zhen De Shou Fat Loss...
More...
Latest Drug Information Updates

Promacta
Promacta (eltrombopag) is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic immune (idiopathic) thrombocytopenic purpura.

Banzel
Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

More...